Microbio Co Ltd (4128) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Microbio Co Ltd (4128) has a cash flow conversion efficiency ratio of -0.010x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-100.20 Million ≈ $-3.16 Million USD) by net assets (NT$10.20 Billion ≈ $321.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Microbio Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Microbio Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Microbio Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Microbio Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Microbio Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Microbio Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metalfrio Solutions S.A
SA:FRIO3
|
0.428x |
|
Infotel SA
PA:INF
|
0.098x |
|
Brinova Fastigheter AB (publ)
ST:BRIN-B
|
0.006x |
|
Andretti Acquisition Corp. II Class A Ordinary Shares
NASDAQ:POLE
|
-0.002x |
|
Burgenland Holding Aktiengesellschaft
VI:BHD
|
N/A |
|
SatixFy Communications Ltd
NYSE MKT:SATX
|
0.081x |
|
Anhui Fengxing Wear Resistant Materials Co Ltd
SHE:002760
|
0.032x |
|
Bait Bakfar Ltd
TA:BKFR
|
0.010x |
Annual Cash Flow Conversion Efficiency for Microbio Co Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Microbio Co Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Microbio Co Ltd (4128) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.20 Billion ≈ $321.50 Million |
NT$85.27 Million ≈ $2.69 Million |
0.008x | -81.28% |
| 2024-12-31 | NT$11.87 Billion ≈ $373.94 Million |
NT$529.90 Million ≈ $16.69 Million |
0.045x | +871.28% |
| 2023-12-31 | NT$13.50 Billion ≈ $425.34 Million |
NT$-78.15 Million ≈ $-2.46 Million |
-0.006x | -157.28% |
| 2022-12-31 | NT$14.01 Billion ≈ $441.34 Million |
NT$141.57 Million ≈ $4.46 Million |
0.010x | +159.17% |
| 2021-12-31 | NT$13.84 Billion ≈ $436.15 Million |
NT$53.98 Million ≈ $1.70 Million |
0.004x | -54.37% |
| 2020-12-31 | NT$12.85 Billion ≈ $404.91 Million |
NT$109.82 Million ≈ $3.46 Million |
0.009x | +6.78% |
| 2019-12-31 | NT$9.04 Billion ≈ $284.89 Million |
NT$72.36 Million ≈ $2.28 Million |
0.008x | +388.65% |
| 2018-12-31 | NT$9.68 Billion ≈ $304.91 Million |
NT$15.85 Million ≈ $499.33K |
0.002x | +238.29% |
| 2017-12-31 | NT$8.30 Billion ≈ $261.53 Million |
NT$-9.83 Million ≈ $-309.70K |
-0.001x | +94.47% |
| 2016-12-31 | NT$8.41 Billion ≈ $265.04 Million |
NT$-180.25 Million ≈ $-5.68 Million |
-0.021x | -18.36% |
| 2015-12-31 | NT$8.94 Billion ≈ $281.77 Million |
NT$-161.90 Million ≈ $-5.10 Million |
-0.018x | +1.39% |
| 2014-12-31 | NT$9.10 Billion ≈ $286.68 Million |
NT$-167.04 Million ≈ $-5.26 Million |
-0.018x | +9.53% |
| 2013-12-31 | NT$8.70 Billion ≈ $274.25 Million |
NT$-176.63 Million ≈ $-5.56 Million |
-0.020x | +3.13% |
| 2012-12-31 | NT$6.32 Billion ≈ $199.08 Million |
NT$-132.36 Million ≈ $-4.17 Million |
-0.021x | +51.99% |
| 2011-12-31 | NT$6.23 Billion ≈ $196.39 Million |
NT$-271.95 Million ≈ $-8.57 Million |
-0.044x | -142.24% |
| 2010-12-31 | NT$5.04 Billion ≈ $158.75 Million |
NT$520.41 Million ≈ $16.40 Million |
0.103x | +211.97% |
| 2009-12-31 | NT$5.26 Billion ≈ $165.69 Million |
NT$-485.10 Million ≈ $-15.28 Million |
-0.092x | -15.56% |
| 2008-12-31 | NT$1.79 Billion ≈ $56.53 Million |
NT$-143.21 Million ≈ $-4.51 Million |
-0.080x | -8.41% |
| 2007-12-31 | NT$1.29 Billion ≈ $40.78 Million |
NT$-95.30 Million ≈ $-3.00 Million |
-0.074x | -1038.56% |
| 2006-12-31 | NT$559.40 Million ≈ $17.62 Million |
NT$4.39 Million ≈ $138.25K |
0.008x | -- |
About Microbio Co Ltd
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; pr… Read more